Skip Navigation

Research Funding

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

June 2014 DMID Council-Approved Concepts

Concepts represent early planning stages for program announcements, request for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Systems Biology and Antibacterial Resistance

For the published request for applications, see the January 27, 2015, Guide announcement, Systems Biology and Antibacterial Resistance (U01).

Nontraditional Therapeutics That Limit Antibacterial Resistance

For the published request for applications, see the November 14, 2014, Guide announcement, Nontraditional Therapeutics That Limit Antibacterial Resistance (R21/R33).

Partnerships for Host-Targeted Therapeutics to Limit Antimicrobial Resistance

For the published request for applications, see the June 5, 2015, Guide announcement, Partnerships for the Development of Host-Targeted Therapeutics to Limit Antibacterial Resistance (R01).

Development of Therapeutic Products for Biodefense and Emerging Infectious Diseases

Broad Agency Announcement

Contact: Alexandra Buck

Objective: To advance the translation of promising therapeutic products against biothreat pathogens and emerging infectious diseases from lead candidate to first-in-human clinical trials.

Description: This initiative will support the necessary development activities to carry a lead candidate product through Phase I clinical testing. Special emphasis will be placed on therapeutics that may fill gaps in our armamentarium, such as therapeutics for filovirus and emerging influenza strains, with particular importance placed on therapies that address antimicrobial resistant pathogens and limit the emergence of antimicrobial resistance.

Activities will be supported that encompass focused nonclinical development and clinical evaluation (through Phase I only) of treatments to address unmet needs to position new therapies toward advanced development and eventual licensure. Offerors must have already identified a promising candidate therapeutic agent and will propose a comprehensive product development plan for moving their therapeutic candidate through human clinical trials.

Methods of Clinical Sample Preparation for Rapid Detection of Bacterial Pathogens

For the published request for proposals, see the August 15, 2014, Solicitation of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals.

Development of Novel Influenza Antivirals

For the published request for proposals, see the August 15, 2014, Solicitation of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals.​

Last Updated June 05, 2015

Last Reviewed January 28, 2015